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Objective: Use of single-dose antibiotic prophylaxis is associated with reduced antibiotic resistance, lower costs,
and fewer problems with drug toxicity and superinfections. We tested the hypothesis that single doses of cefazolin
are as effective as a 24-hour regimen of cefazolin in preventing surgical site infections in adults undergoing car-
diac procedures.
Methods: This random, prospective, clinical study included 838 adult patients undergoing elective coronary ar-
tery bypass grafting, valve operations, or both. These patients were randomly given a single dose of cefazolin (2 g)
or a 24-hour treatment (2-g initial dose, followed by 1 g every 8 hours). Investigators blinded to the drug regimen
diagnosed wound infections according to Centers for Disease Control and Prevention criteria. Patient clinical and
demographic characteristics were noted, with follow-up for 12 postoperative months. The primary objective was
to compare the incidence of surgical infections between groups up to 12 months postoperatively.
Results: A total of 419 patients received single-dose cefazolin, and another 419 received the 24-hour treatment.
Surgical site infection occurred in 35 (8.3%) patients receiving single doses and 15 (3.6%) patients administered
the 24-hour treatment (P ¼ .004). We identified no differences between groups for mortality or duration of hos-
pitalization (preoperative hospitalization, intensive care unit stay, and hospitalization after surgical intervention).
The microorganisms isolated showed a similar distribution in both groups. The germs isolated were gram-positive
cocci in 86% of the surgical site infections.
Conclusions: Single-dose cefazolin used as antibiotic prophylaxis in cardiac surgery is associated with a higher
surgical site infection rate than the 24-hour, multiple-dose cefazolin regimen.Coronary artery bypass grafting and heart valve implanta-
tion are both common procedures. It is estimated that in
the United States there are 468,000 bypass operations and
more than 60,000 valve implantations1 carried out annually;
in Europe the figures are 153,670 and 56,574, respectively.2
Surgical site infections (SSIs) in general are a serious com-
plication after cardiac surgery, with a reported incidence of
0.25% to 25%3,4 and a mortality rate of up to 31%.3,4 Ster-
nal wound infections also constitute an economic burden to
the health care system, with reported costs for their treatment
of US$14,000 to $40,000.5
Antibiotic prophylaxis is used to avoid SSIs.3,4 The first-
generation cephalosporins (cefazolin) are used most
frequently3,4,6,7 because the Staphylococcus species, partic-
ularly Staphylococcus aureus, rank among the most com-
monly found pathogens in cardiac surgery patients4,6,7;
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creased costs and the development of antimicrobial resis-
tence.8,9
In recent years, there has been increased interest in the po-
tential clinical benefits of administering the antibiotic in
a single dose.10-12 The benefits of single-dose antimicrobial
prophylaxis are based on microbial first principles: reduced
antimicrobial resistance, fewer problems with drug toxicity
and superinfections, and reduced cost.3 However, most car-
diac surgery units use multiple-dose antimicrobial prophy-
laxis that continues for 24 to 48 hours and often until all
the drain tubes are removed.3,9 There is no consensus3,4,7,8
on the type of antibiotic prophylaxis, whether a single
dose or multiple doses should be used, or the duration of ad-
ministration. We should also add that many different types
of antibiotics have been evaluated in this respect.13-20
Thus the aim of this study was to test the hypothesis that
single doses of cefazolin are as effective as a 24-hour regi-
men of cefazolin in preventing SSIs in adults undergoing
cardiac procedures. Our study population was drawn from
patients undergoing operations in a tertiary-level Spanish
hospital.
MATERIALS AND METHODS
Patients
The study was carried out between September 2003 and January 2007 in
the Hospital Clı´nico Universitario, Valladolid, Spain, where approximatelyurgery c December 2008
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450 cardiac operations are performed annually on adult patients. This study
was approved by the hospital’s research commission.
All adult patients (>18 years of age) scheduled for cardiac valve surgery,
coronary surgery, or both by means of mean sternotomy were initially in-
cluded in the sample. Exclusion criteria were the presence of an active in-
fection, the administration of antibiotherapy in the 48 hours before
surgical intervention, emergency surgical intervention, or allergy to betalac-
tamics; in addition, we did not include patients with transplants or who did
not wish to participate in the study. All those who participated provided
written informed consent.
Randomized Assignation and Antibiotic Regimens
A computerized table of aleatory numbers was used to randomize alloca-
tion, and the patients were divided into one of 2 groups. The single-dose
group received 2 g of cefazolin intravenously between 20 to 30 minutes after
the induction of anesthesia, whereas the 24-hour group was administered 2 g
of cefazolin intravenously between 20 to 30 minutes after the induction of
anesthesia, followed by 1 g every 8 hours. For all interventions lasting
more than 3 hours, a new dose of 1 g of cefazolin was administered. The
evaluation of the results was carried out by a single researcher who did
not know the antibiotic prophylaxis regimen administered.
Patient Evaluation
During hospitalization, cardiac surgeons examined all patients daily.
Specialists in infectious diseases evaluated and treated, in consultation
with the cardiac surgeons, the patients who had perioperative infectious
pathologies. In addition, cultures of the wound were also drawn when
frankly purulent sternal drainage or dehiscence was observed. Samples
were processed in the microbiology laboratory in accordance with stan-
dard procedures (in positive cultures, the type of microorganisms isolated
were noted). Cardiac surgeons personally followed up with patients in the
cardiac outpatient clinic for at least 1 year after discharge from the hos-
pital.
Definitions of SSIs
The definitions of the Centers for Disease Control and Prevention were
used throughout,21 and the surveillance process was uniform for the dura-
tion of the study. The criteria are described below.
Superficial SSI. The infection covers the skin and subcutaneous cel-
lular tissue and is accompanied by one of the following: purulent drainage
through the incision, positive results of incisional culture, and classic in-
flammatory signs that allow the wound to be opened by the surgeon except
in cases in which the incisional culture was negative.
Deep incisional SSI. The infection involves the deep soft tissues of
the incision with at least 1 of the following: purulent drainage through the
deep incision, a deep incision that spontaneously dehisced or was deliber-
ately opened by the surgeon when the patient had a fever (temperature
38C) or localized pain or tenderness (unless the results of an incisional
culture were negative), or evidence of deep incision infection found in a di-
rect examination or second operation.
Mediastinitis. An organ-space SSI characterized by one of the follow-
ing: positive results of a culture obtained from mediastinal tissue or fluid
during a surgical operation, patient fever (temperature 38C), sternal
pain or instability, mediastinal involvement suggested by a computed tomo-
graphic scan, or organisms cultured from the mediastinal area.The Journal of Thoracic and CaSternal osteomyelitis. An organ-space SSI indicated by persistent
purulent drainage from the sternotomy and confirmed by microbiologic
and histopathologic findings.
Endocarditis. An organ-space SSI characterized by Duke’s critera.22
Stratification of the risk of SSIs. SSIs were stratified according
to the National Nosocomial Infection Surveillance System risk index.23 Be-
cause all surgical wounds included in our study were classified as clean, the
index values ranged from 0 to a maximum of 2.
In addition, for all patients, we noted demographic and clinical character-
istics and the dates of intraoperative and postoperative surgery (Table 1).
Nosocomial events present (sepsis, renal failure, and respiratory failure)
were defined by using conventional criteria.24 The number of days of
TABLE 1. Demographics, clinical characteristics, and operative data
for the patients in terms of the surgical operation performed
Characteristics
Single dose
(n ¼ 419)
24-h Regimen
(n ¼ 419) P value
Preoperative values
Age (y) 67.5  10.5 68.2  10.5 .36
Sex (M/F) 272/147 247/172 .07
Diabetes mellitus 111 (26.5) 125 (29.8) .28
Hypertension 189 (45.1) 178 (42.4) .44
Chronic renal failure 18 (4.3) 22 (5.2) .51
Respiratory disease 76 (18.1) 94 (22.4) .12
Peripheral vascular
disease
25 (5.9) 38 (9.0) .08
Immunosuppression 0 (0) 1 (0.2) .31
Hematologic illness 11 (2.6) 10 (2.3) .82
NNIS Risk index
Category 0 41 (9.7) 45 (10.7) .65
Category 1 248 (59.1) 251 (59.9) .54
Category 2 130 (31.0) 123 (29.3) .60
Intraoperative values
Valve 141 (33.6) 147 (35.1) .66
CABG 169 (40.3) 173 (41.3) .67
ValveþCABG 109 (26.0) 99 (23.6) .42
Unilateral ITA 147 (35.0) 147 (35.0) .52
Bilateral ITA 11 (2.6) 7 (1.6) .23
Total CPB time (min) 92.85  37.58 90.69  36.45 .40
Aortic crossclamp
time (min)
66.73  27.76 64.65  28.05 .28
Hypothermia of CPB 33.13  0.72 33.09  0.58 .29
Hto after CPB 27.07  4.20 26.48  4.07 .05
Postoperative values
Time to extubation (h) 49.8  202.8 41.9  148.8 .53
Intra-aortic balloon pump 5 (1.1) 14 (3.3) .03
Red cell transfusion
Patients 261 (62.3) 216 (51.5) .01
Atrial fibrillation 17 (4.0) 21 (5.0) .30
Respiratory failure 28 (6.6) 23 (5.4) .28
Acute renal failure 21 (5.0) 27 (6.4) .22
Renal replacement
treatment
12 (2.8) 13 (3.1) .50
Sepsis 17 (4.0) 18 (4.2) .50
Values are expressed as numbers (percentages) and means  standard deviation.
NNIS, National Nosocomial Infection Surveillance System; CABG, coronary artery
bypass grafting; ITA, internal thoracic artery; CPB, cardiopulmonary bypass; Hto, he-
matocrit.rdiovascular Surgery c Volume 136, Number 6 1523
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of postsurgical hospitalization were all noted, as was postoperative mortal-
ity at 30, 90, and 365 days after the operation.
Statistical Analysis
Before we started this study, cefazolin was the routinely used antibiotic
for prophylaxis in cardiac surgery in our hospital. We estimated the number
of patients needed for an adequate examination of the hypothesis that cefa-
zolin in single doses should at least equal the SSI rate for cefazolin admin-
istered over 24 hours. Estimating that the SSI rate in cardiac surgery is
around 5%,3,14,17,18,23 a total of 419 patients were required in each group
for the study to be able to show a significant reduction of the SSI rate to
less than 5% with an a level of .20 and b error of .05. The reduction to
less than 5% was chosen in agreement with the median SSI rate reported
by the National Nosocomial Infections Surveillance System for coronary ar-
tery bypass graft operations among patients in risk category 2.23
The degree of statistical significance between the 2 groups was deter-
mined by using the Student t test or the Wilcoxon rank sum test for contin-
uous variables and by using the Fisher’s exact test or c2 test for categorical
variables.
Kaplan–Meier estimates of mortality, along with risk ratios and 95 per-
cent confidence intervals, were used to describe the relative risk of death.
These curves were statistically compared with the log-rank test. Data
were stored and analyzed with SPSS version 14.0 (SPSS, Inc, Chicago, Ill).
RESULTS
Patient Characteristics
Over the study period, a total of 1027 patients were in-
cluded, and 189 were excluded for not receiving the random-
ized prophylactic antibiotherapy regimen, for receiving
another antibiotherapy regimen for surgical prophylaxis, or
for having an incomplete follow-up. A total of 838 patients
completed the study: 419 received cefazolin in single doses,
and 419 received the 24-hour regimen. Table 1 shows their
demographic and clinical characteristics, as well as the vari-
ables associated with the surgical intervention categorized
with respect to the antibiotic regimen used. Both groups
were homogeneous and comparable as far as their demo-
graphic profiles and clinical characteristics were concerned.
Noteworthy findings include the fact that in the single-dose
group the number of patients who had transfusions was sig-
nificantly higher than for those in the 24-hour group (62.3%
vs 51.5%, P ¼ .01, Table 1).
Outcomes
Regarding the prevalence of infection in the analyzed se-
ries (Table 2), of the total number of patients, 50 (5.9%) pre-
sented with an SSI. A total of 35 SSIs were documented
(8.3%) in the single-dose group and 15 (3.6%) in the 24-
hour group (P ¼ .004). The percentages of superficial (P ¼
.007) and deep incisional (P ¼ .04) SSIs were higher in the
single-dose group than in the 24-hour group. Organ-space
SSIs were more frequent in the single-dose group, although
this difference was not statistically significant (Table 2).
The duration of the hospitalization (preoperative hospital-
ization, mean ICU stay, and hospitalization after the opera-
tion) was similar (P> .05) in both groups (Table 2).1524 The Journal of Thoracic and Cardiovascular SMortality
Mortality was similar in both groups (Table 2). Kaplan–
Meier analysis shows that there were no significant differ-
ences between the groups in mortality at 30 days (P ¼
.112 by the stratified log-rank test), 90 days (P ¼ .112 by
the stratified log-rank test), or 365 days (P ¼ .357 by the
stratified log-rank test) (Fig 1).
Microorganisms
The pathogens isolated in the SSIs were similarly distrib-
uted in both groups (P .05, Table 3). In 43 (86%) of the 50
patients with SSIs, the SSIs were gram-positive cocci. The
most frequent microorganisms isolated were Staphylococ-
cus epidermidis, followed by S aureus. The gram-negative
bacilli caused 24% (12/50 cases) of the SSIs. The polymi-
crobial infection rate was similar in both groups: 20
(57.1%) of 35 infections in the single-dose group and 9
(60.0%) of 15 infections in the 24-hour group.
DISCUSSION
The 2 most relevant findings of the study are first that the
administration of cefazolin in a single-dose regimen is asso-
ciated with a higher rate of SSIs compared with rates for pa-
tients receiving the 24-hour regimen (8.3% vs 3.6%).
Nevertheless, mortality was not increased in the single-
dose group during hospitalization (preoperative hospitaliza-
tion, ICU stay, and hospitalization after the operation).
Second, the study confirms that the germs most frequently
TABLE 2. Outcomes of 838 patients receiving single-dose versus 24-
hour prophylaxis
Characteristics
Single dose
(n ¼ 419)
24-h Regimen
(n ¼ 419) P value
Superficial and deep
incisional SSI
21 (5.0) 7 (1.7) .007
Superficial incisional SSI 16 (3.8) 7 (1.7) .04
Deep incisional SSI 5 (1.2) 0 .03
Organ-space SSI* 14 (3.3)* 8 (1.9) .19
Osteomyelitisy 3 (0.7) 2 (0.5) .5
Mediastinitisy 8 (1.9) 5 (1.2) .28
Endocarditis 5 (1.2) 1 (0.2) .10
Total infection 35 (8.3) 15 (3.6) .004
Preoperative
hospitalization (d)
9.7  7.9 10.8  10.3 .11
Mean ICU stay (d) 10.3  10.9 9.1  8.7 .09
Duration of hospitalization
after the operation (d)
14.75  15.8 12.2  14.2 .25
Mortality, 30 d 22 (5.2) 31 (7.4) .12
Mortality, 90 d 29 (6.9) 37 (8.8) .18
Mortality, 365 d 43 (10.3) 48 (11.5) .34
Values are expressed as numbers (percentages) and means  standard deviation. SSI,
Surgical site infection; ICU, intensive care unit. *In the single-dose group mediastinitis
and endocarditis were documented simultaneously in 2 patients. yFor all the patients
who presented with osteomyelitis and mediastinitis simultaneously, an accompanying
deep incisional surgical site infection was also documented.urgery c December 2008
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S epidermidis, followed by S aureus.
In other surgical specialties there is evidence that a single
dose of antibiotic prophylaxis is sufficient to optimally
reduce SSIs.17-19,25,26 A wide body of evidence in the liter-
ature supports this evidence based on both laboratory exper-
iments and clinical trials. Burke27 first outlined the principle
more than 45 years ago based on a series of experiments he
performed using S aureus in guinea pigs. He concluded that
‘‘.the effective period of prophylaxis begins the moment
the bacteria gain access to the tissue and lasts approximately
three hours.’’
The general consensus is that postoperative antibiotic
prophylaxis should be stopped within 24 hours of most
major procedures.3,7-12 However, in cardiac surgery this
clinical practice has not been applied for several reasons.
Cardiac surgeons have argued that there are many risk fac-
tors favoring SSIs in cardiac surgery, including (1) the car-
diopulmonary bypass humoral compromise that occurs in
the immunologic defenses, along with a reduction in
phagocytosis and white blood cell activation, all of which
impair the ability to neutralize infectious organisms; (2) the
use of hypothermia; (3) the risk of postoperative bleeding;
and (4) the length of the surgical procedures.3 Thus al-
though cardiac surgeons have considered their patients to
be high risk and have adopted a policy involving the use
of antibiotics until removal of the chest and central intrave-
nous lines,3,9 recent guidelines have indicated that antibi-
otic prophylaxis can be continued up to 48 hours after
the operation.3
In the last 20 years, the question of optimum duration has
not been adequately explored, with identical antibiotic regi-
mens administered to groups differing only in the duration of
FIGURE 1. Kaplan–Meier estimates of survival among 838 patient receiv-
ing single-dose versus 24-hour prophylaxis.
TABLE 3. Microorganisms isolated according to surgical site infections and antibiotic
Single dose 24-h Regimen
Pathogens
Superficial and deep
incision (n ¼ 21)
Organ space
(n ¼ 14)
Total
(n ¼ 35)
Superficial and deep
incision (n ¼ 7)
Organ space
(n ¼ 8)
Total
(n ¼ 15)
Gram-positive cocci
All 30 (142.8) 5 (35.7) 35 (100.0) 12 (171.4) 6 (75.5) 18 (120.0)
Staphylococcus aureus
All 9 (42.8) 2 (14.2) 11 (31.4) 5 (71.4) 0 6 (40.0)
Methicillin resistant 3 (14.3) 1 (7.1) 4 (11.4) 1 (14.3) 0 1 (6.6)
Methicillin susceptible 6 (28.6) 1 (7.1) 7 (20.0) 4 (57.1) 0 5 (33.3)
Staphylococcus epidermidis
All 19 (90.4) 1 (7.1) 20 (57.1) 5 (71.4) 3 (37.5) 9 (60.0)
Methicillin resistant 11 (52.4) 1 (7.1) 12 (34.3) 2 (28.6) 3 (37.5) 5 (33.3)
Methicillin susceptible 8 (38.1) 0 8 (22.8) 2 (28.6) 0 4 (26.6)
Other Staphylococcus species 0 1 (7.1) 1 (2.8) 1 (14.3) 2 (13.3)
Streptococcus mitis 0 1 (7.1) 1 (2.8) 0 0 0
Enterococcus faecium 0 0 0 1 (14.3) 0 1 (6.6)
Enterococcus faecalis 2 0 2 (5.7) 0 0 0
Gram-negative bacilli
All 6 (28.6) 2 (14.2) 8 (22.8) 2 (28.6) 2 (25.0) 4 (26.6)
Pseudomonas aeruginosa 0 1 (7.1) 1 (2.8) 0 0 0
Klebsiella pneumoniae 1 (4.7) 1 (7.1) 2 (5.7) 1 (14.3) 0 1 (6.6)
Enterobacter cloacae 0 0 0 0 1 (12.5) 1 (6.6)
Proteus mirabilis 2 (9.5) 0 2 (5.7) 0 0 0
Acinetobacter baumannii 1 (4.7) 0 1 (2.8) 1 (14.3) 0 1 (6.6)
Other 2 (9.5) 0 2 (5.7) 0 1 (12.5) 1 (6.6)
Values are expressed as numbers (percentages). None of these differences is significant at a P value of less than .05. Some infections were polymicrobial.The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 6 1525
Acquired Cardiovascular Disease Tamayo et al
A
C
Dprophylaxis.13-20 It has therefore not been clearly established
which regimen of antibiotic prophylaxis is the best.
The studies by Bucknell and associates (cefazolin vs teico-
planin and ticarcillin/clavulanate),13 Kriaras and colleagues
(cefuroxime vs amoxicillin–netilmicin),14 Salminen and co-
workers (ceftriaxone vs vancomycin),15 Saginur and associ-
ates (teicoplanin vs cefazolin),16 Sisto and colleagues
(ceftriaxone vs cefuroxime),17 Hall and coworkers (ceftriax-
one vs flucloxacillin and gentamicin),18 and Beam and asso-
ciates (ceftriaxone vs cefazolin)19 all involve at least 1
antibiotic in the multiple-dose arm that was different from
the antibiotic used in the single-dose arm. Other authors,
such as Nooyen and colleagues,20 in a prospective random-
ized study, compared a single dose and a 3-day course of ce-
furoxime and concluded that in coronary artery bypass
grafting a single dose of cefuroxime is as effective as a 3-
day course in the prevention of wound infection. However,
this study evaluated the SSIs only over 7 postoperative
days. This limitation is important because it is well known
that sternal infections usually manifest themselves from the
second postoperative week onward.3
With these types of study design, whether the specific an-
tibiotic, the duration, or both account for the observed SSI
incidence cannot be determined. Thus no conclusion is pos-
sible concerning the efficacy of the single-dose over the 24-
hour regimen. As we have seen, the results of our study show
a higher rate of SSIs with single-dose prophylaxis compared
with the 24-hour regimen, although this difference does not
extend to either the duration of hospital stay or to mortality.
Our study has the advantage of comparing the same antibi-
otic (cefazolin) and the fact that the main aim was to deter-
mine the efficiency of the antibiotic prophylaxis in a single
dose as opposed to a 24-hour regimen.
Cardiac surgery is essentially a clean operation that
should be associated with an infection rate of less than
5%.7-12 The overall SSI rate varies widely from one unit
to another, with ranges between 0.25% to 25%.2-4 Our
SSI data are within the ranges described in the literature.
Cefazolin was used as the antibiotic because the cephalo-
sporin group of antibiotics, in particular the first- and sec-
ond-generation agents, are the drugs most commonly used
as surgical antibiotic prophylaxis in cardiac surgery.3,7-12
In spite of the extensive number of studies, no cephalosporin
has been proved to be clearly superior in diminishing the rate
of SSIs.3,7-12 The use of vancomycin for prophylaxis in car-
diac surgery is much more controversial, although there are
studies suggesting that vancomycin is superior to the ceph-
alosporins and reduces the infection rate of mediastinitis.28
On the other hand, 2 major problems arising from the use
of vancomycin in surgical prophylaxis deserve serious con-
sideration: its association with adverse effects (hypotension
and red man syndrome)29 and the presence of vancomycin-
resistant enterococci and glycopeptide intermediate–resis-
tant S aureus.3,301526 The Journal of Thoracic and Cardiovascular SuRegarding limitations, we should point out that this study
did not evaluate the efficacy of the single-dose regimen in
emergency cardiac surgery. In addition, it is not a multicenter
study, and it might be necessary to carry out a further study
of such characteristics to confirm the current results.
This randomized, prospective, clinical study was de-
signed to verify the hypothesis that in adults undergoing
elective cardiac procedures a single dose of cefazolin com-
pared with a 24-hour regimen of cefazolin is just as effective
in preventing SSIs. Both groups analyzed were homoge-
neous as far as their demographic and clinical data were con-
cerned, and the sample size was sufficient to compare both
groups. We found a higher rate of SSIs when single-dose ce-
fazolin was used as the antibiotic prophylaxis in cardiac sur-
gery as opposed to its use in multiple doses over 24 hours.
However, there were no differences in mortality rate or
length of hospital stay. The germs most frequently found
to be the cause of SSIs were the gram-positive cocci. The re-
sults indicate that multiple doses of cefazolin over 24 hours
should be used instead of single doses in surgical prophy-
laxis for cardiac surgery procedures.
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